Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use

European Journal of Contraception and Reproductive Health Care

Volumn 20, Issue 1, 2015, Pages 57-63

  Modesto, Waleska ^a   De Nazaré Silva Dos Santos, Priscila ^a   Correia, Vinicius Machado ^a   Borges, Luiza ^a   Bahamondes, Luis ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Copper IUD; Depot medroxyprogesterone acetate; Levonorgestrel releasing intrauterine system; Weight

Indexed keywords

LEVONORGESTREL; METHYLPREDNISOLONE ACETATE; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; COMPARATIVE STUDY; COPPER INTRAUTERINE DEVICE; FEMALE; HORMONAL CONTRACEPTION; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN; WEIGHT VARIATION; ADOLESCENT; ADVERSE EFFECTS; ANALYSIS OF VARIANCE; DRUG EFFECTS; INTRAUTERINE CONTRACEPTIVE DEVICE; RETROSPECTIVE STUDY; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; FEMALE; HUMANS; INTRAUTERINE DEVICES, COPPER; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; RETROSPECTIVE STUDIES; TIME FACTORS; WEIGHT GAIN; YOUNG ADULT;

EID: 84921908588     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2014.951433     Document Type: Article

References (24)

1. Caballero B. The global epidemic of obesity: An overview. Epidemiol Rev 2007; 29: 1-5.
2. May AM, Romaguera D, Travier N, et al. Combined impact of lifestyle factors on prospective change in body weight and waist circumference in participants of the EPIC-PANACEA study. PLoS One 2012; 7: e50712.
3. Lopez L M, Edelman A, Chen M, et al. Progestin-only contraceptives: Effects on weight. Cochrane Database Syst Rev 2013; 2: 7.
4. Le Y C, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet Gynecol 2009; 114: 279-84.
5. Said S, Omar K, Koetsawang S, et al. A multicentred phase III comparative trial of depo-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg. 1. Contraceptive effi cacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1986; 34: 223-35.
6. Vickery Z, Madden T, Zhao Q, et al. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception 2013; 88: 503-8.
7. Nault AM, Peipert JF, Zhao Q, et al. Validity of perceived weight gain in women using long-acting reversible contraception and depot medroxyprogesterone acetate. Am J Obstet Gynecol 2013; 208: 1-8.
8. Hassan DF, Petta CA, Aldrighi JM, et al. Weight variation in a cohort of women using copper IUD for contraception. Contraception 2003; 68: 27-30.
9. Bahamondes L, Castillo S Del, Tabares G, et al. Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. Contraception 2001; 64: 223-25.
10. Yela DA, Monteiro IM, Bahamondes LG, et al. Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil. Rev Assoc Med Bras 2006; 521: 32-36.
11. Pantoja M, Medeiros T, Baccarin M C, et al. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception 2010; 81: 107-11.
12. Baldaszti E, Wimmer-Puchinger B, Lö schke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception 2003; 67: 87-91.
13. Sheng J, Zhang WY, Zhang JP, et al. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the effi cacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009; 79: 189-193.
14. Peipert J F, Zhao Q, Allsworth J E, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117: 1105-13.
15. Suhonen S, Haukkamaa M, Jakobsson T, et al. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: A comparative study. Contraception 2004; 69: 407-12.
16. Dal ' Ava N, Bahamondes L, Bahamondes M V, et al. Body weight and composition in users of levonorgestrel-releasing intrauterine system. Contraception 2012; 86: 350-3.
17. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366: 1998-2007.
18. Clark MK, Dillon JS, Sowers M, et al. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Int J Obes (Lond) 2005; 29: 1252-8.
19. Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol 2009; 200: 329. e1-8.
20. Modesto W, B ahamondes M V, S ilva Dos Santos P, et al. Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate. Eur J Contracept Reprod Health Care 2014; 19: 244-9.
21. M inisté r io da Saú de, Secretaria de Vigilâ ncia em Saú de: Vigitel Brasil 2011: Vigil â ncia de Fatores de Risco e Prote ç ã o para Doen ç as Cr ô nicas por Inqu é rito Telef ô nico. (S é rie G. Estat í stica e Informa ç ã o em Sa ú de). Bras í lia, 2012.
22. Rennie KL, Jebb SA. Prevalence of obesity in Great Britain. Obes Rev 2005; 6: 11-2.
23. NCHS 2 012. Prevalence of obesity in the United States, 2009-2010. National Health and Nutrition Examination Survey (NCHS) Data Brief. No 82, NCHS, 2012.
24. Pelkman C. Hormones and weight change. J Reprod Med 2002; 47: 791-4.